VolitionRx (NYSE:VNRX) Posts Quarterly Earnings Results

VolitionRx (NYSE:VNRX) released its earnings results on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.50 million. VolitionRx had a negative return on equity of 7,185.73% and a negative net margin of 4,557.29%.

VolitionRx Trading Up 4.1 %

NYSE:VNRX opened at $0.75 on Wednesday. VolitionRx has a one year low of $0.55 and a one year high of $2.10. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.69 and a current ratio of 0.69. The firm has a 50-day simple moving average of $1.00 and a 200-day simple moving average of $0.87.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Vanguard Group Inc. grew its holdings in VolitionRx Limited (NYSE:VNRX) by 4.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 542,444 shares of the company’s stock after acquiring an additional 22,046 shares during the period. Vanguard Group Inc. owned about 0.69% of VolitionRx worth $374,000 at the end of the most recent quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.